Peripheral interactions between dextromethorphan, ketamine and amitriptyline on formalin-evoked behaviors and paw edema in rats

Pain

Volumn 102, Issue 1-2, 2003, Pages 179-186

  Sawynok, Jana ^a   Reid, Allison ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Amitriptyline; Dextromethorphan; Formalin evoked behaviors; Ketamine; Paw edema

Indexed keywords

AMITRIPTYLINE; BIOGENIC AMINE; DEXTROMETHORPHAN; FORMALDEHYDE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SEROTONIN; SODIUM CHANNEL BLOCKING AGENT;

ANALGESIA; ANIMAL BEHAVIOR; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; MALE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; RAT;

EID: 0037333257     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0304-3959(02)00373-1     Document Type: Article

References (65)

1. Ahtee L. Dextromethorphan inhibits 5-hydroxytryptamine uptake by human blood platelets and decreases 5-hydroxyindoleacetic acid content in rat brain. J Pharm Pharmacol. 27:1975;177-180.
2. Amann R., Schuligoi R., Lanz I., Donnerer J. Histamine-induced edema in the rat paw - effect of capsaicin denervation and a CGRP receptor antagonist. Eur J Pharmacol. 279:1995;227-231.
3. Azzaro A.J., Smith D.J. The inhibitor action of ketamine HCl on [3H]5-hydroxytryptamine accumulation by rat brain synaptosomal-rich fractions: comparison with [3H]catecholamine and [3H]γ-aminobutyric acid uptake. Neuropharmacology. 16:1977;349-356.
4. Biegon A., Samuel D. Interaction of tricylic antidepressants with opiate receptors. Biochem Pharmacol. 29:1980;460-462.
5. Bryson H.M., Wilde M.I. Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Drugs Aging. 8:1996;459-476.
6. 2+ levels in neuronal culture. Eur J Pharmacol. 219:1992;53-57.
7. Carlton S.M. Peripheral excitatory amino acids. Curr Opin Pharmacol. 1:2001;52-56.
8. Carlton S.M., Coggeshall R.E. Inflammation-induced changes in peripheral glutamate receptor populations. Brain Res. 820:1999;63-70.
9. Carpenter C.L., Marks S.S., Watson D.L., Greenberg D.A. Dextromethorphan and dextrorphan as calcium channel antagonists. Brain Res. 439:1988;372-375.
10. Chaplan S.R., Malmberg A.B., Yaksh T.L. Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat. J Pharmacol Exp Ther. 280:1997;829-838.
11. Choi A., Mitchelson F. Variation in the affinity of amitriptyline for muscarine receptor subtypes. Pharmacology. 48:1994;293-300.
12. Coderre T.J., Katz J., Vaccarino A.L., Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain. 52:1993;259-285.
13. Dallel R., Raboisson P., Clavelou P., Saade M., Woda A. Evidence for a peripheral origin of the tonic nociceptive response to subcutaneous formalin. Pain. 61:1995;11-16.
14. Davidson E.M., Carlton S.M. Intraplantar injection of dextrorphan, ketamine or memantine attenuates formalin-induced behaviors. Brain Res. 785:1998;136-142.
15. Dickenson A.H., Chapman V., Green G.M. The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord. Gen Pharmacol. 28:1997;633-638.
16. Durieux M.E. Inhibition by ketamine of muscarinic acetylcholine receptor function. Anesth Analg. 81:1995;57-62.
17. Eide P.K., Stubhaug A., Breivik H., Øye I. Ketamine: relief from chronic pain through actions at the NMDA receptor. Pain. 72:1998;289-291.
18. Eschalier A., Ardid D., Dubray C. Tricyclic and other antidepressants as analgesics. Sawynok J., Cowan A. Novel aspects of pain management: opioids and beyond. 1999;303-319 Wiley-Liss, New York, NY.
19. Esser M.J., Sawynok J. Acute amitriptyline in a rat model of neuropathic pain: differential symptom and route effects. Pain. 80:1999;643-653.
20. Fisher K., Coderre T.J., Hagen N.A. Targeting the N-methyl-D-aspartate receptor for chronic pain management: preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Manage. 20:2000;358-373.
21. Frenkel C., Urban B.W. Molecular actions of racemic ketamine on human CNS sodium channels. Br J Anaesth. 69:1992;292-297.
22. Hall H., Ogren S.O. Effects of antidepressant drugs on different receptors in the brain. Eur J Pharmacol. 70:1981;393-407.
23. Hara K., Yanagihara N., Minami K., Ueno S., Toyoihira Y., Sata T., Kawamura M., Brüss M., Bönish H., Shigematsu A., Izumi F. Ketamine interacts with the noradrenaline transporter at a site partly overlapping the desipramine binding site. Naunyn-Schmiedeberg's Arch Pharmacol. 358:1998;328-333.
24. Hernandez S.C., Bertolini M., Xiao Y., Pringle K.E., Caruso F.S., Kellar K.J. Dextromethorphan and its metabolite dextrorphan block α3β4 neuronal nicotinic receptors. J Pharmacol Exp Ther. 293:2000;962-967.
25. Hirota K., Lambert D.G. Ketamine: its mechanism(s) of action and unusual clinical uses. Br J Anesth. 77:1996;441-444.
26. Hoyer D. Functional correlates of serotonin recognition sites. J Receptor Res. 8:1988;59-81.
27. Hustveit O., Maurset A., Øye I. Interaction of the chiral forms of ketamine with opioid, phencyclidine, σ and muscarinic receptors. Pharmacol Toxicol. 77:1995;355-359.
28. + current by dextromethorphan in rat dorsal raphe neurones. Neuropharmacology. 39:2000;2302-2308.
29. Jackson D.L., Graff C.B., Richardson J.D., Hargreaves K.M. Glutamate participates in the peripheral modulation of thermal hyperalgesia in rats. Eur J Pharmacol. 284:1995;321-325.
30. 2 receptor. Biol Psychiatry. 49:2001;954-957.
31. Kolesnikov Y., Pasternak G.W. Topical opioids in mice: analgesia and reversal of tolerance by a topical N-methyl-D-aspartate antagonist. J Pharmacol Exp Ther. 290:1999;247-252.
32. 2+ exchange in rat brain cortex synaptosomes. Can J Physiol Pharmacol. 68:1990;1414-1418.
33. Lawand N.B., Willis W.D., Westlund K.N. Excitatory amino acid receptor involvement in peripheral nociceptive transmission in rats. Eur J Pharmacol. 324:1997;169-177.
34. Maling H.M., Webster M.E., Williams M.A., Aaul W., Anderson W. Inflammation induced by histamine, serotonin, bradykinin and compound 48/80 in the rat: antagonists and mechanisms of action. J Pharmacol Exp Ther. 191:1974;300-310.
35. Mao J. NMDA and opioid receptors: their interactions in antinociception, tolerance and neuroplasticity. Brain Res Rev. 30:1999;289-304.
36. McCleane G.J. Topical doxepin hydrochloride reduces neuropathic pain: a randomized, double-blind, placebo controlled study. Pain Clin. 12:2000;47-50.
37. McCleane G.J. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. Br J Clin Pharmacol. 49:2000;574-579.
38. McQuay H.J., Tramer M., Nye B.A., Carrol D., Qiffen P.J., Moore R.A. A systematic review of antidepressants in neuropathic pain. Pain. 68:1996;217-227.
39. Meoni P., Tortella F.C., Bowery N.G. An autoradiographic study of dextromethorphan high-affinity binding sites in rat brain: sodium-dependence and colocalization with paroxetine. Br J Pharmacol. 120:1997;1255-1262.
40. + currents in rat locus coeruleus neurons in vitro. Eur J Pharmacol. 361:1998;157-163.
41. Nishimura M., Sato K., Okada T., Yoshiya I., Schloss P., Shimada S., Tohyama M. Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells. Anesthesiology. 88:1998;768-774.
42. Nishiyama T. Interaction between intrathecal morphine and glutamate receptor antagonists in formalin test. Eur J Pharmacol. 395:2000;203-210.
43. Øye I., Hustveit O., Maurset A., Moberg E.R., Paulsen O., Skoglund L.A. The chiral forms of ketamine as probes for NMDA receptor functions in humans. Kameyama T., Nabeshima T., Domino E.F. NMDA receptor related agents: biochemistry, pharmacology and behavior. 1991;381-389 NPP Books, Ann Arbor, MI.
44. + channels by antidepressant drugs. J Pharmacol Exp Ther. 284:1998;208-214.
45. Park T.J., Shin S.Y., Suh B.C., Suh E.K., Lee I.S., Kim Y.S., Kim K.T. Differential inhibition of catecholamine secretion by amitriptyline through blockage of nicotinic receptors, sodium channels, and calcium channels in bovine adrenal chromaffin cells. Synapse. 29:1998;248-256.
46. Parsons C.G. NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol. 429:2001;71-78.
47. Plesan A., Hedman U., Xu X.J., Weisenfeld-Hallin Z. Comparison of ketamine and dextromethorphan in potentiating the antinociceptive effect of morphine in rats. Anesth Analg. 86:1998;825-829.
48. Price D.D., Mao J., Lu J., Caruso F.S., Frend H., Mayer D.J. Effects of the combined oral administration of NSAIDs and dextromethorphan on behavioral symptoms indicative of arthritic pain in rats. Pain. 68:1996;119-127.
49. Price D.D., Mao J., Mayer D.J. Central neural mechanisms of normal and abnormal pain states. I. Fields H.L., Liebskind J.C. Progress in pain research and management. 1994;61-84 IASP Press, Seattle, WA.
50. Price D.D., Mayer D.J., Mao J., Caruso F.S. NMDA-receptor antagonists and opioid receptor interactions as related to analgesia and tolerance. J Pain Symptom Manage. 19:2000;S7-S11.
51. Pubill D., Canudas A.M., Sureda F.X., Camins A., Pallas M., Escubedo E., Camarasa J. Effect of PCP and sigma ligands on both noradrenaline- and electrically-induced contractions and on [3H]-noradrenaline uptake in rat vas deferens. J Auton Pharmacol. 8:1998;239-244.
52. Puig S., Sorkin L.S. Formalin-evoked activity in identified primary afferent fibers: systemic lidocaine suppresses phase-2 activity. Pain. 64:1995;245-355.
53. Reynolds I.J., Miller R.J. Tricyclic antidepressants block N-methyl-D-aspartate receptors: similarities to the action of zinc. Br J Pharmacol. 95:1988;95-102.
54. 1 receptors. Mayo Clin Proc. 54:1979;669-674.
55. Richelson E., Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol. 104:1984;277-286.
56. Sawynok J., Esser M.J., Reid A.R. Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and a neuropathic pain test in the rat. Pain. 82:1999;149-158.
57. Sawynok J., Reid A.R., Esser M.J. Peripheral antinociceptive action of amitriptyline in the rat formalin test: involvement of adenosine. Pain. 80:1999;45-55.
58. Sawynok J., Esser M.J., Reid A.R. Antidepressants as analgesics: an overview of central and peripheral mechanisms of action. J Psychiatry Neurosci. 2001;21-28.
59. Sawynok J., Reid A.R. Modulation of formalin-induced pain behaviors and paw swelling by local peripheral administration of dextromethorphan, memantine and ketamine in rats. Eur J Pharmacol. 450:2002;153-162.
60. Sindrup S.H. Antidepressants as analgesics. Yaksh T.L., Maze M., Lynch C., Bieguyck J.F., Zampol W.M., Adidman L.J. Anesthesia: biologic foundations. 1997;987-997 Lippincott-Raven, Philadelphia, PA.
61. + channels in rat dorsal root ganglion neurons. Eur J Pharmacol. 401:2000;297-305.
62. Sufka K.J., Schomburg F.M., Giordano J. Receptor mediation of 5-HT-induced inflammation and nociception in rats. Pharmacol Biochem Behav. 41:1991;53-56.
63. Tohda M., Urushihara H., Nomura Y. Inhibitory effects of antidepressants on NMDA-induced currents in xenopus oocytes injected with rat brain RNA. Neurochem Int. 96:1995;53-58.
64. Weisenfeld-Hallin Z. Combined opioid-NMDA antagonist therapies. What advantages do they offer for the control of pain syndromes? Drugs. 55:1998;1-4.
65. Wooltorton J.R.A., Mathie A. Block of potassium current in rat isolated sympathetic neurones by tricyclic antidepressants and structurally related compounds. Br J Pharmacol. 110:1993;1126-1132.